Frost Biologic was founded in 2007 and was originally based on using phenotypic screening to identify small molecules that alter cellular behaviors associated with cancer progression. Since then, Frost has developed robust chemistry and preclinical research capabilities. Molecules derived from this screening approach are thoroughly optimized and put through a rigorous preclinical development program that is designed to yield the best possible clinical candidates.

While Frost is ready to partner or license its programs once a clinical candidate has been nominated and when preclinical proof of concept is complete, Frost also initiates GLP studies and Phase I clinical trials as soon as its programs are ready. See Frost’s Pipeline page for more information on specific programs and their stage of development.

Frost remains privately owned and funded.